By Institution. To the extent permitted by applicable law, Institution will defend Microsoft against any third-party claim to the extent it alleges that: (1) any Customer Data or non- Microsoft software hosted in an Online Service by Microsoft on Institution's behalf misappropriates a trade secret or directly infringes a patent, copyright, trademark, or other proprietary right of a third party; or (2) Institution’s use of any Product or Fix, alone or in combination with anything else, violates the law or damages a third party.
By Institution. The Study may be terminated at any time by Institution after consultation with MedImmune if Institution reasonably believes that such termination is required to protect subject safety or if Medimune is declared bankrupt. Such termination will be effective upon receipt by CRO of written notice thereof from Institution.
By Institution. CRO authorizes Institution to delegate Institution duties under this Agreement to Principal Investigator as appropriate. Institution may not otherwise assign its rights or delegate or subcontract any duties under this Agreement without written permission from CRO. If CRO authorizes delegation or subcontracting, Institution remains responsible to CRO for the performance of all delegated or subcontracted duties.
By Institution. Institution shall list Biocept’s name, and individual Biocept personnel as authors as appropriate, on any scientific manuscript or abstract that is submitted for publication or presentation that includes information that has been either directly or indirectly derived from the Research Support and Services on the Samples and related to the specific SOW under which the Samples were provided and the Research Support and Services were performed under this Agreement and SOW. Biocept shall be notified of such planned inclusion of its, and its personnel’s, name on scientific manuscripts or abstracts, provide permission for such inclusion, and be permitted to review and comment upon any publication or abstract on which its name or personnel are listed prior to submission.
By Institution. Subject to Section 9.3 (Proce- dure), Institution and Investigator each shall indemnify, defend and hold harmless Idorsia and its corporate affiliates, officers, directors, employees, contractors and agents of each (the "Idorsia Indemnitees"), from and against Liabilities as a result of any Claims made or filed against any of the Idorsia In- demnitees arising out of, or caused directly by Institution's or Investigator's (i) breach of this Agreement, including but not limited to failure to obtain IRB/IEC approvals or a signed ICF from each Subject and/or failure to adhere to the terms of the Protocol or to Idorsia's other written instructions concerning the Study Drug; (ii) failure to comply with Applicable Laws; (iii) negligence or willful misconduct; or (iv) use of a product (including the Study 9.2 Ze strany Zdravotnického zařízení. V sou- ladu s ustanoveními článku 9.3 (Postup) jak Zdravotnické zařízení, tak Zkoušející odškodní, obhájí a převezme odpovědnost za společnost Idorsia a její korporátní spřízněné osoby, funkcionáře, členy před- stavenstva, zaměstnance, dodavatele a zá- stupce každé z nich (xxxx označované xxx xxxx „Osoby odškodňované společností Idorsia“) ve vztahu k veškerým Závazkům vzniklým v důsledku jakýchkoli Nároků vznesených nebo podaných proti kterékoli z Osob odškodňovaných společností Idorsia a vzniklých v důsledku nebo způsobených přímo (i) z porušení této Smlouvy Zdravot- nickým zařízením nebo Zkoušejícím, zejména včetně jejich nezajištění souhlasu IRB/IEC nebo podepsaného formuláře ICF Drug) other than those produced or supplied by Idorsia. od každého Subjektu a/nebo nedodržení podmínek Protokolu nebo jiných písemných pokynů společnosti Idorsia týkajících se Hodnoceného přípravku; (ii) nedodržením Příslušných právních předpisů ze strany Zdravotnického zařízení nebo Zkoušejícího; (iii) nedbalostí nebo zá- měrným pochybením ze strany Zdravot- nického zařízení nebo Zkoušejícího; nebo (iv) užíváním produktu (včetně Hodnocen- ého přípravku) jiného, než jsou produkty vyráběné nebo dodávané společností Idorsia.
By Institution. Subject to Section 9.1 (Procedure), Institution and Investigator each shall indemnify, defend and hold harmless Idorsia and its corporate affiliates, officers, directors, employees, contractors and agents of each (the "Idorsia Indemnitees"), from and against Liabilities as a result of any Claims made or filed against any of the Idorsia Indemnitees arising out of, or caused directly by Institution's or Investigator's (i) breach of this Agreement, including but not limited to failure to obtain a signed ICF from each Subject and/or failure to adhere to the terms of the Protocol or to Idorsia's other written instructions concerning the Study Drug; (ii) failure to comply with Applicable Laws; (iii) negligence or willful misconduct; or (iv) use of a product (including the Study Drug) other than those produced or supplied by Idorsia.
By Institution. CRO authorizes Institution to delegate Institution duties under this Agreement to Principal Investigator as appropriate. Institution may not otherwise assign its rights or delegate or subcontract any duties under this Agreement without written permission from CRO. If CRO authorizes delegation or subcontracting, Institution remains responsible to CRO for the performance of all delegated or subcontracted duties.
17.1 Ze strany zdravotnického zařízení. CRO zdravotnickému zařízení povoluje vhodným způsobem delegovat povinnosti zdravotnického zařízení vyplývající z této smlouvy na hlavního zkoušejícího. Zdravotnické zařízení není jinak oprávněno postoupit svá práva nebo delegovat své povinnosti vyplývající z této smlouvy nebo uzavírat subdodavatelské smlouvy na tyto povinnosti bez písemného souhlasu CRO. Pokud CRO povolí delegování nebo uzavírání subdodavatelských smluv, odpovídá zdravotnické zařízení i nadále CRO za plnění všech delegovaných povinností.
By Institution. Institution may not assign any rights or delegate or subcontract any duties under this Agreement without written permission from Pfizer. If Pfizer authorizes any delegation of duties, Institution remains responsible to Pfizer for the performance of those duties.
By Institution. Neither Principal Investigator nor Institution may assign their rights or delegate or subcontract any duties under this Agreement without 17.1 Ze strany zdravotnického zařízení. Hlavní zkoušející ani zdravotnické zařízení nesmějí bez písemného souhlasu CRO postoupit svá práva ani delegovat či subkontrahovat své povinnosti written permission from CRO. If CRO authorizes delegation or subcontracting, the party that delegated or subcontracted its duties remains responsible to CRO for the performance of all delegated or subcontracted duties. podle této smlouvy. Pokud CRO delegování nebo subkontrahování povolí, smluvní strana, která delegovala nebo subkontrahovala své povinnosti, i nadále ponese vůči CRO odpovědnost za plnění všech delegovaných nebo subkontrahovaných povinností.
By Institution. Institution shall post a summary of the Research Study on a publicly- available internet register or website prior to conducting the Research Study, and to post summary results of the Research Study on the same publicly-available internet register or website within one year of completing the Research Study. Institution also agrees to submit the results of the Research Study for publication in the peer reviewed literature or at a scientific congress (a "Publication") in a timely and complete manner, with such Publication appropriately disclosing the strengths and weaknesses of the Research Study methodology. Such Publication shall comply with all applicable standards and guidelines including those of the International Committee of Medical Journal Editors. Institution shall submit to EMD Serono an advance copy of the Research Study summary and summary results prior to posting the summaries, as well as an advanced copy of any proposed Publication at least sixty (60) days before submission to a scientific congress or journal for the purpose of reviewing the summaries and Publication for confidential or proprietary commercial information. Upon EMD Serono’s request, all such confidential or proprietary commercial information shall be removed from the summaries and publication. Additionally, Institution shall provide EMD Serono with a reference citation upon publication. Institution will assist EMD Serono in obtaining re-prints of the Publication.
